Session information

Symposium

[SY23] Symposium 23　Encyclopedic Seamless Drug Development for Organ Agnostic Oncology Precision Medicine - Frontline therapeutics of targeting BRCA（HRD）, PARP, HER2 and NTRK genetic alteration -
【E】

Fri. Feb 18, 2022 8:20 AM - 9:50 AM Room 13 (Gold Room, B2F, The Prince Kyoto Takaragaike)

Chair：Kenji Tamura（Department of Medical Oncology/Innovative Cancer Center, Shimane University Hospital），Chihiro Kondoh（Department of Medical Oncology, National Cancer Center Hospital East）

+Add all to schedule

[SY23-1] Organ-agonistic anti-cancer drug development; HER2 or BRAF targeting

^○Kenji Tamura (Department of Medical Oncology/Innovative Cancer Center, Shimane University Hospital)

[SY23-2] Tumor agnostic drug development targeting BRCA or HRD - breast, pancreatic and prostate cancer

^○Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East)

[SY23-3] Clinical Development of PARP Inhibitors in Ovarian Cancer

^○Keiichi Fujiwara (Department of Gynecologic Oncology, Saitama Medical University)

[SY23-4] Tumor Agnostic Development, An Industry Perspective

^○David Hyman (Department of Loxo Oncology and Lilly Oncology, Loxo Oncology at Eli Lilly)

▲